Investigational ALS Drug May Have Clinical Benefit, FDA Staff Says

(MedPage Today) -- Tofersen, an investigational antisense drug developed to treat amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene (SOD1-ALS), may have clinical benefit, FDA reviewers indicated in briefing documents...
Source: MedPage Today Public Health - Category: American Health Source Type: news